TITLE:
The Role of Mir-34a and Mir-145 as Potential Biomarkers of Meningioma Recurrence
AUTHORS:
Liliane Cristina da Silva, Mucio Luiz de Assis Cirino, Paulo Cezar Novais, Álvaro Fabricio Lopes Rios, Marcus Vinícius Batista Celani, Janaína Regina Lellis, Letícia Passi Turra, Maria de Fátima Galli Sorita Tazima, Fernanda Maris Peria, Carlos Gilberto Carlotti Junior, Daniela Pretti da Cunha Tirapelli
KEYWORDS:
Meningiomas, Tumor Recurrence, microRNA, Cell Pluripotency
JOURNAL NAME:
Advances in Bioscience and Biotechnology,
Vol.16 No.2,
February
6,
2025
ABSTRACT: The expression of miRNAs is associated with a variety of diseases, including neoplasms. In recent years, a large number of abnormally expressed miRNAs have been shown to be effective in understanding the oncogenesis, development, progression and prognosis of meningiomas. Furthermore, it is known that miRNAs act as oncogenes or tumor suppressors and that they regulate essential molecular pathways such as transcription factors involved in the pluripotency phenotype of stem cells. Therefore, the aim of this study was to analyze the expression of microRNAs miR-34a, miR-145 and miR-221 that regulate the pluripotency pathway of stem cells and correlate with tumor recurrence in grade I meningiomas. We used 30 samples, belonging to 15 patients who presented recurrences of grade I meningiomas. We observed low expression levels of miR-34a in the group of tumor recurrences when compared to control individuals and primary tumors, which may be associated with the tumor suppressor role of this miR. The miR-145 also showed decreased expression levels between the control group and the group of tumor recurrences. We also observed decreased expression levels in miR-145 between the control group and the primary tumors group. MiR-221 did not differ between the studied groups. MiR-34a and miR-145 microRNAs that regulate the stem cell pluripotency pathway are shown to be hypo expressed in tumor recurrences of grade I meningiomas and are shown to be good candidates for prognosis and recurrence biomarkers in meningiomas.